Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.
Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and cardiometabolic disorders (Glucophage®, metformin); (Concor®, bisoprolol); (Euthyrox®, levothyroxine); (Saizen® and Serostim®, somatropin).
With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.
Hospira is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness. Bringing proven leadership and experience, Hospira provides solutions to help improve the productivity, safety and effectiveness of patient care. In early 2007, Hospira acquired Mayne Pharma to become the world leader in specialty generic injectable pharmaceuticals.
President Europe, Middle East & Africa
Commercial manager Europe, Middle East & Africa
Access Health Care AG was created in April 2006 to provide innovative, research based pharmaceutical companies access to, what will be for them, new geographical markets for their products.
Company’s main focus is the distribution, selling and marketing of products into key geographical markets. Access Health Care specializes in the key market segments of dermatology, gynaecology, oncology and urology.